- Research article
- Open Access
Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
Journal for ImmunoTherapy of Cancer volume 3, Article number: 54 (2015)
Myeloid-derived suppressor cells (MDSC) and M2 monocytes/macrophages are two types of suppressive myeloid antigen presenting cells that have been shown to promote tumor progression and correlate with poor prognosis in cancer patients. Tumor antigen specific monoclonal antibodies (mAb) have emerged as important agents for cancer therapy. In addition to the direct inhibition of tumor growth, the Fc portions of the therapeutic mAbs, such as the IgG1 portion of the anti-epidermal growth factor receptor (EGFR) mAb cetuximab, might interact with the Fc-gamma receptors (FcγR) on myeloid cells and modulate their suppressive activity.
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) on the UPCI 08–013 NCT01218048 trial were treated with single-agent cetuximab before surgery. Blood were collected pre- and post-cetuximab treatment to analyze frequency of monocytic MDSC (CD11b+CD14+HLA-DRlo/-), granulocytic MDSC (LIN−CD11b+CD15+) and CD11b+CD14+HLA-DRhi monocytes by flow cytometry. Besides, CD11b+CD14+HLA-DRhi monocytes were sorted for qPCR analysis of IL-10 and IL-12B transcripts. MDSC were generated in vitro with or without coated hIgG1 and tested for suppressive activity in mixed leukocyte reaction (MLR). Naïve monocytes from HNSCC patients co-cultured with tumor cell lines in the presence of cetuximab or hIgG1 were analyzed for M1/2 surface markers and cytokines.
We observed significantly increased monocytic MDSC in non-responders and decreased granulocytic MDSC in responders after cetuximab treatment. In addition, circulating CD11b+CD14+HLA-DRhi monocytes of cetuximab responders displayed attenuated M2 polarization, with decreased CD163+ expression and IL-10 transcripts after cetuximab treatment. This beneficial effect appeared to be FcγR dependent, since CD16 ligation reproduced the reversal of suppressive activity of MDSC in vitro. CD14+ naïve monocytes from the co-cultures of tumor cells, cetuximab and HNSCC patient PBMC or purified monocytes were skewed to an M1-like phenotype, with increased expression of HLA-DR, CD86 and production of IL-12 p70. Likewise, reduced M2 features (expression of CD163 and production of IL-10) were found after crosslinking CD16 on the surface of monocytes to cetuximab-coated tumor cells.
Our studies demonstrate a novel function of cetuximab in ameliorating suppressive phenotypes of FcγR bearing myeloid cells in cancer patients, which is associated with better clinical outcome of cetuximab-treated patients.
Clinical trial registry
#NCT01218048. Registered 7 October 2010.
Despite recent advances in surgery, chemotherapy and radiotherapy, the overall 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) remains at about 50 %. Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has become an important targeted therapy for multiple types of solid tumors and has been FDA approved for treating locally advanced and recurrent/metastatic HNSCC. However, response rates are only 15–20 % [1, 2], and its mechanism of action has not been determined [3, 4]. Besides inhibition of EGFR tyrosine phosphorylation and the subsequent downstream signaling, the human IgG1 Fc portion of cetuximab can activate NK cell-mediated antibody dependent cell-mediated cytotoxicity (ADCC) in a Fc-gamma receptor (FcγR)-dependent manner , triggering enhanced antigen presentation and resulting in an adaptive tumor-specific immune response . However, since FcγRs are also widely expressed on myeloid antigen presenting cells (APC) in addition to NK cells, cetuximab is also likely to modulate their phenotype and function.
Myeloid APC with potent immunosuppressive activities, including myeloid-derived suppressor cells (MDSC) and M2 macrophages (MΦ)/monocytes (Mo), are induced by multiple tumor-derived soluble factors from the tumor microenvironment, and are utilized by the tumor cells to facilitate immune evasion and to promote tumor progression [7–9]. Increased abundance of MDSC and M2 MΦ/Mo is associated with poor clinical outcome [10–12] and is a major obstacle to existing cancer therapies [8, 13]. Therefore, they represent novel therapeutic targets for manipulating the host immune response against tumor cells. MDSC is a heterogeneous population of immature myeloid cells first identified in tumor-bearing mice as CD11b+Gr-1+ and can be subdivided into two major classes: granulocytic and monocytic MDSC. Granulocytic MDSC inhibit T cell responses mainly through reactive oxygen species (ROS) [14, 15], while monocytic MDSC suppresses T cell by depleting L-arginine via arginase-I and iNOS [16, 17]. In HNSCC patients, LIN−CD11b+CD15+ cells have been characterized as granulocytic MDSC , while CD11b+CD14+HLA-DRlo/- cells have been identified as monocytic MDSC with immunosuppressive functions . M1/M2 polarization plays an important role in modulating anti-tumor immune responses. M1, the classically activated MΦ/Mo induced by IFN-γ and bacterial products, display high antigen presentation efficiency due to upregulation of MHCII (HLA-DR) and co-stimulatory molecules (CD80 and CD86), express high levels of IL-12 and low IL-10, and thus activate Tc1/Th1 anti-tumor responses. In contrast, M2, the alternatively activated MΦ/Mo induced by anti-inflammatory cytokines, produce high levels of IL-10 and low levels of IL-12, and thus inhibit development of Th1 cells and CTL responses and facilitate tumor progression . Therefore, polarization of MΦ/Mo towards an M1 phenotype is indispensable to enhance efficacy of anti-tumor immunotherapy.
Since CD16 receptor binds to the Fc portion of cetuximab and its intracellular immunoreceptor tyrosine-based activation motif (ITAM) has been suggested to induce DC maturation , we hypothesized that cetuximab can skew these myeloid cells away from immunosuppressive capacity of MDSC and M2 cells. In this study, we investigated the effects of cetuximab on the well-reported abundance of granulocytic and monocytic MDSC as well as the M1/M2 polarization of monocytes in the peripheral circulation in HNSCC patients, taking advantage of a phase II trial of neoadjuvant cetuximab. In addition, we also utilized in vitro generated MDSC in the presence or absence of CD16 ligation in a suppression assay and co-culture of tumor cells and PBMC or purified monocytes from HNSCC patients with or without cetuximab, to further investigate the mechanism of cetuximab mediated MDSC activity.
Circulating monocytic MDSC increase in cetuximab non-responding patients
Since monocytic myeloid-derived suppressor cells (MDSC) have been shown to be enriched in the peripheral blood of cancer patients, we investigated the population of circulating monocytic MDSC, the other subset of MDSC enriched in HNSCC patients, characterized as CD14+HLA-DRlo/-, in HNSCC patients on the UPCI 08–013 trial, a cetuximab single agent trial in which the patients received weekly doses of cetuximab for 3 to 4 weeks before surgery . First, we examined the baseline frequency of circulating CD14+HLA-DRlo/- in the CD11b+ compartment in the cohort of patients on the 08–013 trial of neoadjuvant cetuximab, as compared with healthy donors by flow cytometry (gating strategy shown in Additional file 1: Figure S1A). As expected, stage III/IV HNSCC patients showed significantly higher CD14+HLA-DRlo/- cells in circulating CD11b+ cells at baseline compared with healthy donors (Fig. 1a). We then tested whether cetuximab treatment altered the level of circulating monocytic MDSC in the HNSCC patients.
Interestingly, a significant increase of monocytic MDSC in CD11b+ cells (p = 0.01) and in whole peripheral blood mononuclear cells (PBMC) (p = 0.01) was observed in non-responder patients after cetuximab treatment. Surprisingly, the baseline level of CD14+HLA-DRlo/- cells within CD11b+ PBMC was higher in responders than in non-responders (p = 0.02). However, the cetuximab clinical responders did not show upregulation of circulating monocytic MDSC. On the contrary, 7 of the 10 responders had decreased levels of monoctyic MDSC in the peripheral circulation post-cetuximab, but this finding did not reach statistical significance (Fig. 1b and c). The baseline levels of CD16 expression on circulating monocytic MDSC are similar between responders and non-responders (Additional file 1: Figure S2), indicating different clinical responses to cetuximab treatment are not due to different baseline level of CD16. Our data indicates that cetuximab can overcome the enrichment of circulating monocytic MDSC in patients with advanced HNSCC, with the possibility of decreasing these cells in a subset of clinical responders.
Decreased circulating granulocytic MDSC in HNSCC patients after cetuximab treatment
Having demonstrated the changes of monocytic MDSC in the patients of the 08–013 trial, we next studied the abundance of circulating granulocytic MDSC, the other subset of MDSC, in our cohort of HNSCC patients. First, we compared the frequency of granulocytic MDSC (LIN−CD11b+CD15+) in the circulation of healthy donors and HNSCC patients prior to cetuximab treatment (gating strategies shown in Additional file 1: Figure S1A). Consistent with previous report , we observed much higher levels of circulating LIN−CD11b+CD15+ in HNSCC patients than in healthy donors (Fig. 2a, p < 0.01). Next, we examined the frequency of circulating granulocytic MDSC in this cohort of HNSCC patients pre- and post-cetuximab treatment. Interestingly, the overall percentage of granulocytic MDSC significantly decreased in the circulation of the 24 patients tested (p = 0.008). However, a significant and consistent decrease in the abundance of circulating granulocytic MDSC was observed only in the cetuximab responders (n = 8, p = 0.008) as compared to cetuximab-resistant patients (n = 16) (Fig. 2b and c). Our findings suggest that cetuximab treatment might modulate the development of granulocytic MDSC in HNSCC patients.
Decreased CD163+ cells and IL-10 transcripts in circulating CD11b+CD14+HLA-DRhi monocytes in cetuximab-treated responders
Next, we investigated another major subpopulation of CD14+ circulating monocytes, specifically CD14+HLA-DRhi cells that are likely to be precursors of tissue macrophages, to analyze whether cetuximab treatment alters their M1/M2 phenotypic skewing in HNSCC patients on the cetuximab neoadjuvant trial. First, we analyzed expression of CD163, a scavenger receptor usually used as an M2 surface marker and up-regulated by anti-inflammatory cytokines such as IL-10 and IL-6 , on circulating CD11b+CD14+HLA-DRhi monocytes. Although there was no significant difference in frequency of CD163+ cells in CD11b+CD14+HLA-DRhi monocytes in the circulation of HNSCC patients tested overall (n = 29) pre- and post-cetuximab treatment, we observed a significant decrease in percentage of CD163+ cells in circulating CD11b+CD14+HLA-DRhi monocytes in the cetuximab clinical responders (n = 9, p = 0.049) (Fig. 3a and b). These findings suggest that cetuximab treatment might lessen M2 skewing of circulating monocytes or potentially induce a more beneficial anti-inflammatory environment in the HNSCC patients’ tumors.
In order to investigate the M1/M2 skewing of circulating CD11b+CD14+HLA-DRhi monocytes in the cetuximab-treated patients more definitively, we sorted the CD11b+CD14+HLA-DRhi from the patient PBMC pre- and post-cetuximab treatment by FACS sorting and purified the RNA for real time qPCR analysis of IL-12B (produced by M1 or mature dendritic cells) and IL-10 (mainly produced by M2) transcripts. While IL-12 transcripts in circulating CD11b+CD14+HLA-DRhi monocytes were too low to be determined, expression of IL-10 transcripts was down-regulated in CD11b+CD14+HLA-DRhi monocytes from HNSCC patient PBMC (n = 14, p = 0.02) after cetuximab treatment. Moreover, circulating CD11b+CD14+HLA-DRhi monocytes from cetuximab responders showed consistent and significant decreased IL-10 transcripts post-cetuximab treatment (n = 6, p = 0.03), while some of the cetuximab non-responders (n = 8) manifested increased IL-10 transcripts in circulating CD11b+CD14+HLA-DRhi monocytes (Fig. 3c). These findings indicate that the CD11b+CD14+HLA-DRhi monocytes in the peripheral circulation of cetuximab-treated patients displayed less M2 skewing, including with decreased expression of IL-10 transcripts.
FcγR ligation can reverse the suppressive effects of IL-6 + GM-CSF-induced MDSC on T cell proliferation
Since FcγR are widely expressed on myeloid cells, and the Fc portion of cetuximab, human IgG1 (hIgG1), can bind to FcγR such as FcγRIII (CD16) and trigger the downstream signaling, we hypothesized that cetuximab may directly act on the FcγR on the myeloid cells to ameliorate their suppressive phenotypes in cancer patients. In order to test this possibility, we took advantage of an established in vitro induction procedure for MDSC from peripheral blood of healthy donors to test whether ligating the FcγR to hIgG1 Fc domains changes the phenotypes and suppressive functions of the in vitro induced MDSC. We coated hIgG1 (10 μg/mL) to polystyrene flasks and plated the PBMC isolated from healthy donors (n = 3) in the hIgG1-coated flasks or uncoated flasks, in the presence or absence of 10 ng/mL IL-6 and GM-CSF for 7 days. Surface markers were analyzed by flow cytometry and CD33+ myeloid cells were isolated and cultured with the CFSE-labeled autologous T cells to test suppressive activity. Expression of HLA-DR was downregulated in the presence of IL-6 and GM-CSF, which is consistent with the expectation that MDSC have deficient HLA-DR expression, while ligation of FcγR by polyvalent hIgG1 increased HLA-DR expression in these MDSC inducing conditions (Fig. 4a). Furthermore, while IL-6 and GM-CSF-induced MDSC strongly suppressed proliferation of autologous T cells (Fig. 4b, p = 0.03), the presence of hIgG1 coated surfaces during the in vitro induction ameliorated the suppressive effects of cytokine-induced MDSC on T cells (Fig. 4b, p = 0.02). Notably, we observed a concomitant down-regulation of CD16, but not CD32a or CD32b on the surface of CD33+ cells cultured in the hIgG1-coated flask (Fig. 4c), indicating hIgG1 mainly interacts with CD16 but not CD32a/b on the myeloid cells. Taken together, our data indicates that cetuximab can skew circulating myeloid cells away from MDSC-like suppressive phenotypes toward an FcγR-dependent manner.
Cetuximab skews monocytes co-cultured with tumor cells to an M1 instead of M2 phenotype
Having demonstrated that CD11b+CD14+HLA-DRhi monocytes in the peripheral circulation of cetuximab responders showed attenuated M2 skewing with decreased CD163+ cells and IL-10 transcripts after cetuximab treatment, we next investigated whether cetuximab alters M1/M2 skewing of naïve monocytes in vitro. Total PBMC or purified monocytes from HNSCC patients with new active diseases (n = 9) were co-cultured with PCI15B or JHU029 (HNSCC cell lines with high EGFR expression) for 3 days with 10 μg/mL cetuximab or hIgG1 (isotype control), before analysis of surface markers on CD14+ monocytes by flow cytometry. As expected, expression of HLA-DR and CD86, which are well known as markers of M1 macrophages, were up-regulated on CD14+ monocytes within PBMC co-cultured with tumor cells in the presence of cetuximab (p = 0.004). In addition, upregulation of PD-L1, which correlates with the activation status of monocytes , was more pronounced on monocytes incubated with cetuximab versus control mAb (p = 0.004). Moreover, naïve monocytes co-cultured with tumor cells showed decreased expression of CD163, the scavenger receptor expressed on M2 suppressive microphages, only in the presence of cetuximab (p = 0.004, Fig. 5a and b). Similar changes of surface markers on CD14+ monocytes were also observed in the co-cultures of tumor cells and purified monocytes with cetuximab in the absence of NK cells (Fig. 5c and d), indicating M1/M2 skewing of naïve monocytes altered by cetuximab is NK-independent.
Cetuximab down-regulates surface expression of CD16 on monocytes only in the presence of EGFR-expressing tumor cells
Activation of NK cells by cross-linking of CD16 with cetuximab-coated tumor cells resulting in loss of surface CD16 due to internalization [23, 24]. Thus, we investigated whether monocytes can be activated by cetuximab-coated tumor cells in a similar CD16-dependent manner. Surface expression of CD16 was analyzed on CD14+ monocytes from PBMC and purified monocytes from HNSCC patients cultured with or without PCI15B or JHU029 in the presence of 10 μg/mL cetuximab or hIgG1. CD14+ monocytes showed significantly decreased CD16 surface expression when cultured with cetuximab-coated tumor cells (Fig. 5e, p = 0.004), concomitant with upregulation of M1 and down-regulation of M2 markers (Fig. 5a-d). In contrast, PBMC or purified monocytes treated with cetuximab in the absence of EGFR-expression tumor cells did not show altered CD16 surface expression (Fig. 5f) and no difference in M1 and M2 markers were observed (data not shown). These findings indicate that cetuximab-coated tumor cells polarize naïve monocytes to M1 cells by direct crosslinking of CD16 on the monocytes by the hIgG1 Fc portion of cetuximab.
Cetuximab down-regulates surface expression of CD16 on monocytes only in the presence of EGFR-expressing tumor cells
Since production of IL-12 p70 and IL-10 are key functional mediators of M1 and M2 cells , respectively, we also examined IL-12 p70 and IL-10 cytokines in the supernatants of co-culture between tumor cells and PBMC or purified monocytes, incubated with or without cetuximab. PBMC or purified monocytes from HNSCC patients co-cultured with tumor cells had increased production of IL-12 p70 (Fig. 6a, p = 0.02) and decreased production of IL-10 (Fig. 6b, p = 0.02) in the presence of cetuximab. Taken together, our data suggest that cetuximab can skew naïve monocytes toward an M1-polarized phenotype when co-cultured with EGFR+ tumor cells, including upregulation of M1 surface markers and cytokines and reduced M2 characteristics.
Pander et al. previously suggested that M2 macrophages are activated in the tumor microenvironment by addition of cetuximab to bevacizumab and chemotherapy in a randomized phase III clinical trial of metastatic colorectal cancer (CRC) patients , which seems to contradict with our current findings. However, the actual correlation of M2 macrophages in the tumor microenvironment with cetuximab treatment was not shown. In addition, their study was a combinational therapy of cetuximab, bevacizumab and chemotherapy, instead of a single agent therapy of cetuximab as we present here. Therefore, we cannot rule out the possibility that their in vivo observations are a complex result of multiple therapeutic interventions, rather than cetuximab alone. Instead, in our study, we took advantage of a prospective cetuximab single agent trial (UPCI 08–013) to explore the effects of cetuximab on myeloid cells in vivo and demonstrated that cetuximab treatment attenuated M2 phenotypes of circulating CD11b+CD14+HLA-DRhi monocytes in 08–013 responders with decreased expression of CD163 and IL-10 transcripts (Fig. 3). Pander et al. used in vitro differentiated M2 macrophages to co-culture with cetuximab-coated tumor cells instead of naïve monocytes as we did in this study. The upregulation of PD-L1 and IL-10 expression on M2 macrophages might be due to general activation of monocytes instead of specific skewing towards M2 by cetuximab. In our in vitro co-culture studies, we observed upregulation of PD-L1 but decreased production of IL-10 and increased production of IL-12 p70 in the presence of cetuximab-coated tumor cells (Figs. 5 and 6), indicating cetuximab coated on tumor cells skews naïve monocytes towards an M1 but not M2 polarization, and PD-L1 is not a necessary marker for M2 MΦ/Mo. In addition, we used a higher concentration of cetuximab in our in vitro studies, (10 μg/mL versus their 1 μg/mL) and studied different disease contexts (HNSCC versus CRC), which might also contribute to the different observations. Taken together, we conclude that cetuximab could ameliorate suppressive phenotypes of antigen presenting myeloid cells, skewing them away from MDSC and M2 MΦ/Mo, which is firmly supported by both in vivo and in vitro findings.
Due to small sample size (a cohort of 29 patients) and variable preliminary nature of the patients, some of our analyses only showed a trend of increase or decrease, but did not turn out to be statistically significant. Thus, we were not able to segregate the patients into different groups according to certain characteristics. Therefore, those findings might not be convincing enough to be applied to all the patients and require validation in independent cohorts. However, we still observed some consistent changes in responders or non-responders after cetuximab treatment, such as decreased granulocytic MDSC in the PBMC of responders (decreased in every responder patients after cetuximab treatment). These findings can be used as biomarkers for prognosis. Moreover, since this trial is a cetuximab single agent trial, we can infer much more clear indications about the immunologic effects of cetuximab alone on the patients, without complicating effects of chemotherapy and/or radiotherapy.
Activated NK cells are able to enhance DC maturation and mature DC can secrete IL-12 to elongate the duration of NK activation, as a reciprocal crosstalk mechanism of NK: DC crosstalk [6, 27]. Therefore, a question is raised whether cetuximab-mediated attenuation of suppressive phenotypes of myeloid cells is dependent on NK cells. Notably, the purified CD14+ monocytes (purity: up to 97 %) could be skewed to M1 phenotypes with increased expression of M1 surface markers and production of IL-12 p70 even in the absence of NK cells. In addition, down-regulation of CD16, but not CD32a/b, was observed on in vitro induced MDSC with FcγR: hIgG1 ligation (Fig. 4c) and monocytes co-cultured with cetuximab-coated tumor cells (Fig. 5e), indicating CD16 is internalized after interacting with the hIgG1 Fc portion of cetuximab and hIgG1 mainly interact with CD16 instead of CD32a or CD32b. In conclusion, our data suggest skewing of myeloid cells away from suppressive phenotypes by cetuximab is NK-independent. However, cetuximab-activated NK cells would be expected to enhance the M1 polarization of naïve monocytes with further enhanced up-regulation of HLA-DR and CD86 as well as amount of secreted IL-12 p70 (Figs. 5 and 6).
According to our findings, increased frequency of circulating monocytic MDSC is correlated to poor clinical response, though we also observed higher frequency of circulating monocytic MDSC in responders at baseline level (Fig. 2). We also noted that a higher frequency of Treg have been observed at baseline in cetuximab clinical responders compared to non-responders . It is possible that responders have stronger initial induced anti-tumor immune responses and concomitantly more immunosuppressive cells (MDSC and Treg) at baseline (before cetuximab treatment). Besides, decreased M2 polarization of CD11b+CD14+HLA-DRhi monocytes in the peripheral circulation was also correlated with better clinical outcome (Fig. 3), which is consistent with previous reports that increased abundance of MDSC and M2 MΦ/Mo correlated with poor prognosis in cancer patients [10, 29]. In conclusion, cetuximab enhances anti-tumor immune responses in HNSCC patients not only by activating NK-mediated ADCC, but also by ameliorating suppressive phenotypes of myeloid antigen presenting cells, which is associated with better outcome in treated HNSCC patients. Since circulating monocytic MDSC were more abundant in patients did not respond to cetuximab treatment, MDSC depletion or inhibition reagents should be considered to use in combination with cetuximab to improve the efficacy of cetuximab therapy.
In this study, we provide a novel insight for how cetuximab modulates the immune system in HNSCC patients by ameliorating the MDSC and M2 immunosuppression, and its clinical significance, based on our in vivo and in vitro observations. First, we demonstrate increased frequency of circulating monocytic MDSC in non-responders and reduced abundance of circulating granulocytic MDSC in cetuximab-treated HNSCC patients compared to pretreatment levels. Second, CD11b+CD14+HLA-DRhi monocytes in the peripheral blood of cetuximab responders showed less M2 polarization with decreased expression of CD163 and IL-10 transcripts. Third, our in vitro FcγR: hIgG1 ligation was able to reverse the immunosuppression of the IL-6 and GM-CSF induced MDSC, indicating the effect of cetuximab on the development of MDSC is FcγR-dependent. Fourth, cetuximab skewed naïve monocytes towards M1 phenotypes, with upregulation of surface expression of HLA-DR and CD86 and production of IL-12 p70 as well as decreased M2 characteristics (expression of surface CD163 and IL-10 cytokine), concomitant with down-regulation of surface CD16 expression. These data suggest an important role for therapeutic tumor-targeted mAb in promoting immunostimulatory phenotypes of APC in treated patients.
Patients and specimens
All patients were seen in the Department of Otolaryngology at the University of Pittsburgh Medical Center, and specimens from patients were obtained by informed consent under the IRB approved UPCI protocol 99–069. This study was approved by University of Pittsburgh IRB and it was a single site trial. PBMC were obtained from HNC patients receiving neoadjuvant cetuximab on a prospective phase II clinical trial (UPCI #08-013, NCT 01218048). Tumors were biopsied immediately before, and again after 4 weeks, of cetuximab therapy. Clinical response was analyzed by comparing paired CT scans pre/post cetuximab, and quantifying tumor measurement by a dedicated head and neck radiologist blinded to patient status. Anatomic tumor measurements were recorded in two dimensions and the cohort segregated into clinical “responders,” who demonstrated reduction in tumor volume, or “non-responders,” whose tumors grew during this therapy. This is a validated method to correlate clinical response, and this was the primary, pre-specified endpoint in the clinical trial (UPCI #08-013), funded and peer-reviewed by NIH R01 DE019727. Furthermore, the approach has been published [28, 30, 31]. Traditional RECIST criteria are not appropriate for short “window of opportunity” (neoadjuvant) biomarker therapeutic trials seeking to identify earlier response biomarkers associated with objective clinical response. Clinico-pathologic features of the responders and non-responders are described in Table 1.
Peripheral venous blood samples were collected from a cohort of 9 stage III/IV HNSCC patients with newly diagnosed, untreated disease for in vitro studies of tumor cell and PBMC/monocyte studies.
Collection of peripheral blood mononuclear cells (PBMC)
Venous blood from HNSCC patients was drawn into heparinized tubes and centrifuged on Ficoll-Hypaque gradients (GE Healthcare Life Sciences, Piscataway, NJ). PBMC were recovered, washed in RPMI-1640 medium (Sigma, St. Louis, MO), and either used immediately for experiments or resuspended in freezing media containing 10 % DMSO and 90 % FBS, transferred to Mr. Frosty containers (Thermo Scientific, Waltham, MA), and stored at −80 °C. Frozen PBMC were thawed in 37 °C waterbath and transferred to 15 mL conical tube. Pre-warmed RPMI-1640 medium containing 10 % FBS was added dropwise to the thawed cells. After centrifuging the cells to remove the freezing media, the cells can be used for flow cytometry or in vitro experiment.
Antibodies and flow cytometry
The following anti-human antibodies were used for staining: CD68-FITC, CD14-PercP-Cy5.5, HLA-DR-APC, CD15-PE-Cy7, CD11b-PercP-Cy5.5, CD163-BV421, CD14-APC, HLA-DR-PE, CD33-BV421 and PD-L1-BV421 purchased from Biolegend (San Diego, CA), CD11b-PE, CD3-Alexa Fluor 700, CD19-Alexa Fluor 700, CD19-Alexa Fluor 700, CD163-Alexa Fluor 647, CD16-PE-Cy7, CD3-PE, CD19-PE and CD56-PE purchased from BD Biosciences (San Jose, CA), CD14-PE-TR and CD16 PE-TR purchased from Life Technologies (Carlsbad, CA) and CD86-FITC purchased from R&D systems (Minneapolis, MN). CD32-a-FITC Ab was purchased from Stemcell technologies, (Vancouver, Canada). CD-32-B (F-4) was purchased from Santa Cruz Biotechnology, Santa Cruz, CA, and secondary Ab anti-mouse F(ab’)2 was purchased from Thermo fisher scientific (MA, USA).
Intracellular staining of CD68 was performed as follows: PBMC were stained with surface marker antibodies, fixed with fixation/permeabilization buffer (eBioscience), washed, and stained for intracellular antigens in 1X permeabilization buffer. Cells were analyzed on an LSR Fortessa (BD) flow cytometer, and data analyzed using Flow Jo (Treestar, Ashland, OR). Dead cells were excluded based on viability dye staining (Zombie Aqua Fixable Viability Dye, Biolegend).
Sorting of CD11b+CD14+HLA-DRhi circulating monocytes from patients and quantitative real-time PCR
PBMC from HNSCC patients was obtained pre- and post-cetuximab treatment (on the UPCI 08–013 trial Table 2) were thawed and stained with CD11b-PercP-Cy5.5, CD14-APC and HLA-DR-PE antibodies. CD11b + CD14 + HLA-DRhicells were sorted using Beckman Coulter MoFlo Astrios (Brea, CA). Sorted cells were then lysed in RLT lysis buffer and subjected to RNA purification using RNeasy Mini Kit (Qiagen, Valencia, CA) and Purelink DNase Set (Invitrogen, Grand Island, NY). The concentration and purity of RNA was determined by measuring absorbance at 260 and 280 nm. RNA was used for first strand cDNA synthesis using random hexamers and MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA) according to manufacturer’s instructions. PCR probes for IL-12B (Hs01011518_m1), IL-10 (Hs00961622_m1) and GUSB (Hs99999908_m1) were purchased from Applied Biosystem for TaqMan® Gene Expression Assay. Real-time PCR cycling was performed using StepOne™ Real-Time PCR Systems (Applied Biosystems, Carlsbad, CA). GUSB was amplified as an internal control. All of the experiments were performed in triplicates. Relative expression of the target genes to endogenous control gene (GUSB) was calculated using the ΔCT method: relative expression = 2−ΔCT, where ΔCT = CT (target gene) − CT (GUSB).
hIgG1 ligation assay
10 μg/mL human IgG1 (Southern Biotech, Birmingham, AL) dissolved in 1X ELISA coating buffer (Biolegend, San Diego, CA) was added to T-75 flasks. Then the flasks were incubated for 2 h at 37 °C or overnight at 4 °C. Coated flasks were washed with sterile PBS 3 times before use.
In vitro monocyte induction of MDSC and MDSC suppression assay
PBMC isolated from healthy donors (n = 3) were plated in the hIgG1-coated flasks or uncoated flasks at 5X105 cells/mL in complete medium for 7 days, supplied with or without 10 ng/mL IL-6 and GM-CSF (R&D systems, Minneapolis, MN). Medium and cytokines were refreshed every 2–3 days. After 7 days, all cells were harvested from the cultures. Adherent cells were removed using trypsin. Some of the harvested cells were subjected to analysis of surface markers by flow cytometry. The other cells were stained with CD33-BV421, CD3-PE, CD19-PE and CD56-PE and CD3−CD19−CD56−CD33+ cells from each culture were isolated using FACS sorting (Beckman Coulter MoFlo Astrios, Brea, CA).
Fresh T cells were isolated from PBMC of autologous donors by Human T cell Enrichmen Kit (Stemcell Technologies, Vancouver, Canada) and were CFSE-labeled (2 μM, Life Technologies, Carlsbad, CA) and seeded in 96-well plates at 1X105 cells per well. CD33+ cells isolated from the cultures indicated above were added to these wells at a 1:2 ratio of CD33+ cells: T cells. T cell stimulation was provided by anti-CD3/CD28 stimulation beads (Invitrogen, Carlsbad, CA) at a 1:1 ratio of T cells: beads. Suppression assay wells were analyzed by flow cytometry for T cell proliferation after 3 days.
Tumor cell: PBMC/purified monocyte co-culture studies
PBMC were isolated from 9 HNSCC patients with newly diagnosed diseases. CD14+ monocytes were purified from PBMC using EasySep human CD14 positive selection kit (Stemcell Technologies, Vancouver, Canada). PCI15B or JHU029 were seeded in 96-well plates at 1X104 cells per well. PBMC were added to these cells at a ratio of 1:10 (tumor cells: PBMC) and purified monocytes were added at a ratio of 1:5 (tumor cells: monocytes) with 10 μg/mL cetuximab or hIgG1 (Southern Biotech, Birmingham, AL). Cells were harvested for flow cytometry analysis of surface markers and supernatants were collected and stored in −80 °C after cultured for 3 days.
IL-12 p70 and IL-10 in the supernatants of the co-cultures indicated above were tested using Human IL-12 p70 ELISA Kits and Human IL-10 ELISA Kits (Thermo Scientific, Rockford, IL), per manufacturer’s instructions.
Averages were calculated as means. Two-group comparison was performed using paired Wilcoxon signed rank text in GraphPad Prism (GraphPad, La Jolla, CA). Experimental data with more than 2 comparison groups were analyzed using one-way ANOVA with post hoc pairwise comparisons using Tukey’s multiple comparison test. P-values < 0.05 were considered to be significant. *p < 0.05, **p < 0.01.
Myeloid-derived suppressor cells
Epidermal growth factor receptor
Head and neck squamous cell carcinoma (HNSCC)
Mixed leukocyte reaction
Antibody dependent cell-mediated cytotoxicity
Antigen presenting cells
Reactive oxygen species
Immunoreceptor tyrosine-based activation motif
Peripheral blood mononuclear cells
Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–7.
Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008;112(12):2635–45.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.
Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, et al. Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol. Oct;41(5):678-84.
Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19(7):1858–72.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–68.
Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. 2010;59(10):1593–600.
Ochando JC, Chen SH. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res. 2012;54(1–3):275–85.
Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. 2011;60(10):1419–30.
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.
Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7.
Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(−)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35–45.
Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989–99.
Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235–49.
Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116(10):2777–90.
Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641–54.
Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol. 2011;89(2):311–7.
Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580–9.
Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14:94–108.
Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 2000;67(1):97–103.
Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010;51(1):154–64.
Mota G, Moldovan I, Calugaru A, Hirt M, Kozma E, Galatiuc C, et al. Interaction of human immunoglobulin G with CD16 on natural killer cells: ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing. Scand J Immunol. 2004;59(3):278–84.
Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599–608.
Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–37.
Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res. 2011;17(17):5668–73.
Chwee Ming Lim RS, Andres M Salazar and Robert L. Ferris. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells. Oncoimmunology. 2013;2:e24677.
Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, et al. CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75(11):2200–10.
Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012;7(10):e47045.
Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, et al. STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients. Can Immun Res. 2015;3(8):936–45.
Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, et al. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol. 2012;48(11):1136–45.
Written informed consent was obtained from the patientss for publication of their individual details (age and gender) in this manuscript. The consent form is held by the authors (PI-Dr. Robert Ferris) and is available for review by the Editor-in-Chief.
This study is supported by NIH grant R01 DE019727 and P50CA097190. This project used the UPCI Flow Cytometry Facility that is supported in part by award P30CA047904. Jing Li is supported by the China Scholarship Council.
Financial Support: Funded by NIH grant R01 DE019727 and P50 CA097190.
The authors declare that they have no competing interests.
JL was involved in concept, design and performing of experiments, and wrote the manuscript. RS and AE were involved in performing experiments and revising the manuscript. RLF supervised the study, was involved in concept and design of experiments, critically involved in writing and editing of the manuscript. All authors read and approved the final manuscript.
Gating strategies of monocytic MDSC and granulocytic MDSC in the peripheral blood. Gating strategies of flow cytometry analysis of monocytic MDSC (CD11b+CD14+HLA-DRlo/-) and granulocytic MDSC (Lin−CD11b+CD15+) from HNSCC patients were plotted in A and B, respectively. Figure S2. Similar baseline expression of CD16 on circulating monocytic MDSC in 08–013 responsers and non-responders. Summary data of frequency of CD16+ cells and MFI of CD16 in CD14+HLA-DRlo/- cells in responders (n = 10) and non-responders (n = 19) of UPCI 08–013 trial pre-cetuximab treatment. Statistical significance was determined by Mann Whitney test. (PPTX 553 kb)
About this article
Cite this article
Li, J., Srivastava, R.M., Ettyreddy, A. et al. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. j. immunotherapy cancer 3, 54 (2015). https://doi.org/10.1186/s40425-015-0097-6
- Monoclonal antibody
- Myeloid derived suppressor cells